PMID- 33670625
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210310
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Electronic)
IS  - 2077-0383 (Linking)
VI  - 10
IP  - 4
DP  - 2021 Feb 18
TI  - Cytokines and Chemokines Involved in Hepatitis B Surface Antigen Loss in Human 
      Immunodeficiency Virus/Hepatitis B Virus Coinfected Patients.
LID - 10.3390/jcm10040833 [doi]
LID - 833
AB  - It has been reported that hepatic flare (HF), attributable to the development of 
      immune reconstitution inflammatory syndrome (IRIS) in human immunodeficiency 
      virus (HIV)/hepatitis B virus (HBV) coinfected patients, occurs frequently after 
      the start of anti-retroviral therapy (ART). We have observed several cases of 
      hepatitis B surface antigen (HBsAg) loss after IRIS. However, the factors leading 
      to HBsAg clearance remain unknown. We measured CD4+ and CD8+ T cells, cytokines 
      and chemokines in 16 patients coinfected HIV-1 and HBV with IRIS, and analyzed 
      the factors leading to HBsAg clearance after IRIS. There was no significant 
      difference in the CD4+ and CD8+ T cell counts between the HBsAg clearance and 
      non-clearance groups, while the serum concentrations of almost all cytokines and 
      chemokines in the HBsAg clearance group were higher than in the HBsAg 
      non-clearance group at any time of observation. In particular, IP-10 at the ALT 
      peak, GM-CSF and IL-12 one month after the ALT peak and TNF-alpha and GM-CSF after 
      the ALT concentrations fell to within normal limits, were significantly higher in 
      the HBsAg clearance group. It seems that HBsAg loss after IRIS requires continued 
      immune responses against HBV, involving Th1 cytokines.
FAU - Urata, Noboru
AU  - Urata N
AD  - Department of Gastroenterology, National Hospital Organization, Nagoya Medical 
      Center, Nagoya 460-0001, Japan.
AD  - Department of Virology and Liver Unit, Graduate School of Medical Sciences, 
      Nagoya City University, Nagoya 467-8602, Japan.
FAU - Watanabe, Tsunamasa
AU  - Watanabe T
AUID- ORCID: 0000-0002-7659-914X
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. 
      Marianna University School of Medicine, Kawasaki 216-8511, Japan.
FAU - Hirashima, Noboru
AU  - Hirashima N
AD  - Department of Gastroenterology, National Hospital Organization, Nagoya Medical 
      Center, Nagoya 460-0001, Japan.
FAU - Yokomaku, Yoshiyuki
AU  - Yokomaku Y
AD  - Department of Infectious Diseases and Immunology, National Hospital Organization, 
      Nagoya Medical Center, Nagoya 460-0001, Japan.
FAU - Imamura, Junji
AU  - Imamura J
AD  - Department of Infectious Diseases and Immunology, National Hospital Organization, 
      Nagoya Medical Center, Nagoya 460-0001, Japan.
AD  - Department of Infectious Diseases and Immunology, National Hospital Organization, 
      Sendai Medical Center, Sendai 983-8520, Japan.
FAU - Iwatani, Yasumasa
AU  - Iwatani Y
AUID- ORCID: 0000-0001-9269-4828
AD  - Department of Infectious Diseases and Immunology, National Hospital Organization, 
      Nagoya Medical Center, Nagoya 460-0001, Japan.
FAU - Shimada, Masaaki
AU  - Shimada M
AD  - Department of Gastroenterology, National Hospital Organization, Nagoya Medical 
      Center, Nagoya 460-0001, Japan.
FAU - Tanaka, Yasuhito
AU  - Tanaka Y
AD  - Department of Virology and Liver Unit, Graduate School of Medical Sciences, 
      Nagoya City University, Nagoya 467-8602, Japan.
AD  - Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto 
      University, Kumamoto 860-8556, Japan.
LA  - eng
GR  - JP19fk0210034/Japan Agency for Medical Research and Development/
GR  - JP20fk0310101/Japan Agency for Medical Research and Development/
GR  - 19H03640/Ministry of Education, Culture, Sports, Science and Technology/
PT  - Journal Article
DEP - 20210218
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC7922731
OTO - NOTNLM
OT  - HBsAg
OT  - chemokine
OT  - cytokine
OT  - hepatitis B virus
OT  - human immunodeficiency virus
OT  - immune reconstitution syndrome
COIS- Yasuhito Tanaka: Research funding from Chugai Pharmaceutical Co., Ltd., 
      Fujirebio, Inc., and Gilead Sciences. Lecture fees from Fujirebio, Inc. and 
      Gilead Sciences. The other authors declare no conflict of interest.
EDAT- 2021/03/07 06:00
MHDA- 2021/03/07 06:01
PMCR- 2021/02/18
CRDT- 2021/03/06 01:08
PHST- 2020/12/21 00:00 [received]
PHST- 2021/02/09 00:00 [revised]
PHST- 2021/02/13 00:00 [accepted]
PHST- 2021/03/06 01:08 [entrez]
PHST- 2021/03/07 06:00 [pubmed]
PHST- 2021/03/07 06:01 [medline]
PHST- 2021/02/18 00:00 [pmc-release]
AID - jcm10040833 [pii]
AID - jcm-10-00833 [pii]
AID - 10.3390/jcm10040833 [doi]
PST - epublish
SO  - J Clin Med. 2021 Feb 18;10(4):833. doi: 10.3390/jcm10040833.